
Eileen M. O'Reilly, MD
Medical Oncologist
Titles
Winthrop Rockefeller Endowed Chair of Medical Oncology; Co-Director, Medical Initiatives, David M. Rubenstein Center for Pancreatic Cancer Research; Section Head, Hepatopancreaticobilary & Neuroendocrine Cancers
Clinical Expertise
Pancreatic Cancer; Gallbladder Cancer; Bile Duct Cancer; Primary Liver Cancer; Gastrointestinal Neuroendocrine Cancers
We post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
New Patient Appointments
Scheduling a visit is easy. Click below or call us to get started.
Dr. O'Reilly accepts the following list of insurance providers. Select your insurance provider to see more details.
Payor Type: Commercial
In Network Coverage Type(s): HMO, EPO PPO, POS, Transplant
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): PPO
Payor Type: Commercial
In Network Coverage Type(s): HMO, PPO
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, EPO, HMO
Payor Type: Commercial
In Network Coverage Type(s): HMO, EPO PPO, POS
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO
Payor Type: Commercial
In Network Coverage Type(s): Supplemental
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, HMO
Payor Type: Commercial
In Network Coverage Type(s): POS, EPO, HMO
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, EPO, HMO
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): PPO, HMO
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): PPO, HMO, DSN
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO
Payor Type: Commercial
In Network Coverage Type(s): PPO
Payor Type: Commercial
In Network Coverage Type(s): HMO, EPO
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): HMO
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): PPO
Payor Type: Commercial
In Network Coverage Type(s): EPO, HMO, PPO, POS
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): HMO, PPO
Payor Type: Commercial
In Network Coverage Type(s): PPO EPO
Payor Type: Commercial
In Network Coverage Type(s): HMO
Payor Type: Commercial
In Network Coverage Type(s): PPO
Payor Type: Commercial
In Network Coverage Type(s): EPO
Payor Type: Commercial
In Network Coverage Type(s): EPO
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): PPO, HMO
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): State Government
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, EPO
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): State Government
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): State Government
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): Federal Government
Payor Type: Commercial
In Network Coverage Type(s): Supplemental
Payor Type: Commercial
In Network Coverage Type(s): PPO/OAP
Payor Type: Other
In Network Coverage Type(s): PPO, POS, EPO, HMO
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): TBD
Payor Type: Commercial
In Network Coverage Type(s): HMO/EPO
Payor Type: Commercial
In Network Coverage Type(s): PPO, EPO
Payor Type: Commercial
In Network Coverage Type(s): State Government
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, HMO
Payor Type: Commercial
In Network Coverage Type(s): PPO, HMO
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, HMO
Contact and Location
- 646-888-4182 Office Phone
- Speaks English

Memorial Sloan Kettering has locations throughout New York City, Long Island, New Jersey, and Westchester. These locations offer many services, including screening, chemotherapy, and medical testing.
See all locationsAbout Me
Education
MD, Trinity College, Ireland
Residencies
Internal Medicine - St. James's Hospital
Fellowships
Internal Medicine/Medical Oncology - St. Vincent's Hospital; Medical Oncology - Memorial Sloan Kettering Cancer Center; Medicine - Cornell University Medical Center
Board Certifications
Internal Medicine (Ireland)
I am a medical oncologist whose research and clinical activities focus on treating pancreatic and hepatobiliary cancers. I work very closely with a team of surgeons, oncologists, and radiation therapists to determine and provide the best treatment for people with these diseases.
Read more
My research initiatives include integrating molecular and genetic-based therapies into the treatment of pancreas cancer, developing adjuvant and neoadjuvant therapies, and identifying biomarkers that may be used to select therapy. I am the principal investigator of multiple phase I, II, and III pancreatic cancer clinical trials and have authored and co-authored more than 300 articles, editorials, and book chapters.
In addition to caring for patients at MSK and conducting research, I am Chair of the Human Research Protection Program, the Institutional Review and Privacy Board, and the Continuing Medical Education Committee. I also teach and mentor national and international oncology fellows, junior faculty, residents, and house staff and have received numerous teaching awards.
Outside of MSK, I collaborate with groups and experts around the world to improve outcomes for people with pancreas and hepatobiliary cancers. Nationally, I am Co-Chair of the NCI Alliance Co-Operative Group Gastrointestinal Cancers Committee and a member of the NCI Gastrointestinal Cancers Steering Committee. I also serve on the medical and scientific advisory board of the Pancreatic Cancer Action Network, National Comprehensive Cancer Network Pancreas panel, American Society of Clinical Oncology Guidelines Committee, and the scientific board of the National Pancreas Foundation. I received my medical degree from Trinity College at Dublin University in Ireland, where I was born.
Awards and Honors
- Castle Connolly: America's Top Doctors (2023)
- Castle Connolly: New York Magazine Top Doctors (2005-2020)
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
- Clinical Trials Investigated by Dr. O'Reilly
- A Phase 1 Study of ELI-002 7P Immunotherapy in People with Digestive Cancers
- A Phase I Study of AB680 in Combination with AB122 Immunotherapy, Nab-Paclitaxel, and Gemcitabine in People with Advanced Pancreatic Cancer
- A Phase I Study of MVT-5873 Alone or with Chemotherapy in Patients with Pancreatic Cancer and Other CA19-9 Positive Tumors
- A Phase I Study to Evaluate Different Immunotherapy and Chemotherapy Combinations for Previously Untreated Metastatic Pancreatic Cancer
Read more
- A Phase IA Study of ELI-002 Immunotherapy to Treat RAS-Mutated Pancreatic Cancer and Other Solid Tumors
- A Study of Pancrelipase Enzyme Replacement Therapy in People with Advanced Pancreatic Cancer
- Clinical Trials Co-Investigated by Dr. O'Reilly
- A Phase I Study of ASP3082 in People with Solid Tumors with KRAS G12D Mutations
- A Phase I Study of Conformal Radiation Therapy to the Liver and Chemotherapy to Treat Pancreatic Cancer that Has Spread to the Liver
- A Phase I Study of ONC-392 Immunotherapy in People with Advanced Pancreatic Cancer
- A Phase I/II Study of BA3011 in Patients with Advanced Cancer
- A Phase I/II Study of LYT-200 in People with Solid Tumors
- A Phase I/II Study of OBI-999 in People with Solid Tumors
- A Phase IB Study of CX-5461 in People with Advanced Pancreatic Cancer Containing Certain Genetic Mutations
- A Phase II Study of Olaparib or Placebo in Patients with Surgically Removed Pancreatic Cancer Who Have a BRCA1, BRCA2 or PALB2 Mutation
- A Phase II Study of Pembrolizumab Immunotherapy and OLApaRib (POLAR) Maintenance Therapy for Patients with Metastatic Pancreatic Cancer
- A Phase II Study of Pembrolizumab, Lenvatinib, and Belzutifan in People with Pancreatic Cancer or Biliary Cancer
- A Phase II Study of Zolbetuximab plus Nab-paclitaxel and Gemcitabine to Treat Metastatic Pancreatic Cancer
- A Phase II/III Study Comparing Different Therapies for Metastatic Pancreatic Cancer
- A Phase III Study of Chemotherapy After Surgery versus Chemotherapy Before and After Surgery for Operable Pancreatic Cancer
- A Phase III Study of Standard Chemotherapy with or without NIS793 for the Initial Treatment of Metastatic Pancreatic Cancer
- A Study Comparing Two Standard Chemotherapy Treatments for Newly Diagnosed Metastatic Pancreatic Cancer

Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Visit PubMed for a full listing of Dr. O'Reilly’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
At MSK, we’re committed to delivering the best care to every patient. We use feedback from our patients to continue to improve our care. We also post patient reviews online to help you make healthcare choices. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Eileen M. O'Reilly discloses the following relationships and financial interests:
-
Alpha Metrics and Consulting
Ownership / Equity Interests -
American Association for Cancer Research
Provision of Services -
AstraZeneca
Provision of Services -
Boehringer Ingelheim
Provision of Services -
Cend Therapeutics, Inc.
Provision of Services -
HMP Oncology Learning Network
Provision of Services -
Imedex, Inc.
Provision of Services -
MENA Hereditary Cancer Conference
Provision of Services -
Merck & Co Inc.
Provision of Services -
NOXXON Pharma AG
Provision of Services
-
Novartis
Provision of Services -
Paradigm Medical Communications, LLC
Provision of Services -
Physicians' Education Resource
Provision of Services -
Research to Practice
Provision of Services -
Shanghai Jo'Ann Medical Technology Co., Ltd
Provision of Services -
Silenseed Ltd.
Provision of Services -
WebMD
Provision of Services -
ZielBio, Inc.
Provision of Services -
twoXAR, Inc.
Provision of Services
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].